NasdaqGS:NUVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$3.4b

Last Updated

2021/07/28 22:43 UTC

Data Sources

Company Financials +

Executive Summary

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. More Details


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has NuVasive's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NUVA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: NUVA's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

1.4%

NUVA

2.4%

US Medical Equipment

0.9%

US Market


1 Year Return

8.1%

NUVA

30.8%

US Medical Equipment

37.8%

US Market

Return vs Industry: NUVA underperformed the US Medical Equipment industry which returned 30.8% over the past year.

Return vs Market: NUVA underperformed the US Market which returned 37.8% over the past year.


Shareholder returns

NUVAIndustryMarket
7 Day1.4%2.4%0.9%
30 Day-5.3%3.4%0.3%
90 Day-8.8%3.0%2.1%
1 Year8.1%8.1%31.7%30.8%40.0%37.8%
3 Year1.0%1.0%73.0%68.9%63.8%53.5%
5 Year4.2%4.2%150.1%138.5%124.6%99.7%

Long-Term Price Volatility Vs. Market

How volatile is NuVasive's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NuVasive undervalued compared to its fair value and its price relative to the market?

25.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NUVA ($65.4) is trading below our estimate of fair value ($88.19)

Significantly Below Fair Value: NUVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NUVA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NUVA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NUVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NUVA is good value based on its PB Ratio (4x) compared to the US Medical Equipment industry average (4.5x).


Future Growth

How is NuVasive forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

66.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NUVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: NUVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NUVA's is expected to become profitable in the next 3 years.

Revenue vs Market: NUVA's revenue (6.8% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: NUVA's revenue (6.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NUVA's Return on Equity is forecast to be low in 3 years time (14.3%).


Past Performance

How has NuVasive performed over the past 5 years?

-27.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NUVA is currently unprofitable.

Growing Profit Margin: NUVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NUVA is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare NUVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUVA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).


Return on Equity

High ROE: NUVA has a negative Return on Equity (-5.98%), as it is currently unprofitable.


Financial Health

How is NuVasive's financial position?


Financial Position Analysis

Short Term Liabilities: NUVA's short term assets ($781.6M) exceed its short term liabilities ($224.9M).

Long Term Liabilities: NUVA's short term assets ($781.6M) do not cover its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: NUVA's debt to equity ratio (105.3%) is considered high.

Reducing Debt: NUVA's debt to equity ratio has increased from 102.6% to 105.3% over the past 5 years.

Debt Coverage: NUVA's debt is well covered by operating cash flow (24.1%).

Interest Coverage: NUVA's interest payments on its debt are not well covered by EBIT (0.6x coverage).


Balance Sheet


Dividend

What is NuVasive current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NUVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NUVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NUVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NUVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NUVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Chris Barry (48 yo)

2.67yrs

Tenure

US$4,819,006

Compensation

Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD4.82M) is about average for companies of similar size in the US market ($USD5.31M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NUVA's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: NUVA's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NuVasive, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NuVasive, Inc.
  • Ticker: NUVA
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$3.381b
  • Shares outstanding: 51.65m
  • Website: https://www.nuvasive.com

Number of Employees


Location

  • NuVasive, Inc.
  • 7475 Lusk Boulevard
  • San Diego
  • California
  • 92121
  • United States

Listings


Biography

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade ret...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/28 22:43
End of Day Share Price2021/07/28 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.